16:24 EST Tandem Diabetes (TNDM) up 11% at $20.59 after Q4 results and guidance
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- TNDM Upcoming Earnings Report: What to Expect?
- Tandem Diabetes price target raised to $20 from $16 at Stifel
- Tandem Diabetes coverage transferred with a Buy at TD Cowen
- Tandem Diabetes Care: Multi‑Phase Growth Reacceleration Driven by Patch Pump Launch and Margin Recovery Supports Upgraded $25 Target
- Tandem Diabetes price target raised to $25 from $18 at Bernstein